BG99074A - Recombinant human hiv neutralizing monoclonal antibodies for prophylaxy and treatment of hiv infection - Google Patents

Recombinant human hiv neutralizing monoclonal antibodies for prophylaxy and treatment of hiv infection

Info

Publication number
BG99074A
BG99074A BG99074A BG9907494A BG99074A BG 99074 A BG99074 A BG 99074A BG 99074 A BG99074 A BG 99074A BG 9907494 A BG9907494 A BG 9907494A BG 99074 A BG99074 A BG 99074A
Authority
BG
Bulgaria
Prior art keywords
treatment
recombinant human
prophylaxy
hiv
monoclonal antibodies
Prior art date
Application number
BG99074A
Other languages
Bulgarian (bg)
English (en)
Inventor
Emilio Emini
Anthony Conley
George Mark
L. Johnson
David Pfarr
Original Assignee
Merck & Co. Inc.
Medimmune,Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co. Inc., Medimmune,Inc. filed Critical Merck & Co. Inc.
Publication of BG99074A publication Critical patent/BG99074A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036Retroviridae, e.g. leukemia viruses
    • C07K16/1045Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BG99074A 1992-04-01 1994-09-28 Recombinant human hiv neutralizing monoclonal antibodies for prophylaxy and treatment of hiv infection BG99074A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86170192A 1992-04-01 1992-04-01
PCT/US1993/002629 WO1993019785A1 (en) 1992-04-01 1993-03-23 Recombinant human hiv-neutralizing monoclonal antibodies for prevention and treatment of hiv infection

Publications (1)

Publication Number Publication Date
BG99074A true BG99074A (en) 1995-11-30

Family

ID=25336532

Family Applications (1)

Application Number Title Priority Date Filing Date
BG99074A BG99074A (en) 1992-04-01 1994-09-28 Recombinant human hiv neutralizing monoclonal antibodies for prophylaxy and treatment of hiv infection

Country Status (19)

Country Link
EP (1) EP0577243A3 (sv)
JP (1) JPH06217791A (sv)
KR (1) KR950700761A (sv)
CN (1) CN1081716A (sv)
AU (2) AU3928593A (sv)
BG (1) BG99074A (sv)
CA (1) CA2093099A1 (sv)
CZ (1) CZ239694A3 (sv)
FI (1) FI944561A0 (sv)
HU (1) HUT70461A (sv)
IL (1) IL105145A0 (sv)
MX (1) MX9301858A (sv)
NO (1) NO943653L (sv)
NZ (1) NZ251582A (sv)
RU (1) RU94045907A (sv)
SK (1) SK116294A3 (sv)
WO (1) WO1993019785A1 (sv)
YU (1) YU22693A (sv)
ZA (1) ZA932308B (sv)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69916306T2 (de) * 1998-10-30 2005-05-04 Novozymes A/S Niedrigallergene proteinvarianten
RU2221873C2 (ru) * 2001-04-24 2004-01-20 Закрытое акционерное общество "АСГЛ-Фармацевтические Инновации" Способ получения каталитических антител (варианты), антигены для иммунизации и нуклеотидная последовательность
US7560529B2 (en) 2001-04-24 2009-07-14 FDS Pharma Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence
FR2844455B1 (fr) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
US8332159B2 (en) 2003-02-20 2012-12-11 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Method for enhancing efficacy of preparation of monoclonal antibody
JP2010536885A (ja) * 2007-08-24 2010-12-02 ノバルティス アーゲー V3ループに改変を有するhivenvタンパク質
CN102272134B (zh) 2008-12-09 2013-10-16 吉里德科学公司 Toll样受体调节剂
US10421803B2 (en) 2014-01-31 2019-09-24 The Rockefeller University Broadly neutralizing glycan-dependent 8ANC195 antibody variants that bind to an epitope spanning both HIV-1 Env subunits
MX2017000026A (es) * 2014-07-11 2017-05-01 Gilead Sciences Inc Moduladores de receptores tipo toll para el tratamiento de virus de inmunodeficiencia humana (vih).
MX2017003284A (es) 2014-09-16 2017-06-28 Gilead Sciences Inc Formas solidas de modulador de receptor tipo toll.
WO2021227138A1 (zh) * 2020-05-09 2021-11-18 江苏省疾病预防控制中心(江苏省公共卫生研究院) 针对新型冠状病毒的单克隆抗体或其抗原结合部分

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3853779T2 (de) * 1987-05-29 1995-09-07 Baylor College Medicine Hiv-1 neutralisierende monoklonale antikörper.
EP0311228A3 (en) * 1987-10-09 1990-05-02 Repligen Corporation Recombinant polypeptides and their uses, including assay for aids virus
WO1990015078A1 (en) * 1989-06-05 1990-12-13 Scott Charles F Jr HUMAN MONOCLONAL ANTIBODIES TO HIV-1MN gp 120
WO1991019797A1 (en) * 1990-06-15 1991-12-26 New York University Heterohybridomas producing human monoclonal antibodies to hiv-1
EP0624193A1 (en) * 1992-01-29 1994-11-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Aamp-1, a protein with local homologies to hiv-1 env and nef proteins

Also Published As

Publication number Publication date
ZA932308B (en) 1994-09-30
YU22693A (sh) 1997-01-08
EP0577243A3 (en) 1994-11-02
HU9402824D0 (en) 1994-11-28
MX9301858A (es) 1994-03-31
CN1081716A (zh) 1994-02-09
KR950700761A (ko) 1995-02-20
AU3563093A (en) 1993-10-07
HUT70461A (en) 1995-10-30
RU94045907A (ru) 1996-11-10
AU3928593A (en) 1993-11-08
SK116294A3 (en) 1996-11-06
NZ251582A (en) 1997-07-27
CZ239694A3 (en) 1995-07-12
FI944561A (sv) 1994-09-30
EP0577243A2 (en) 1994-01-05
FI944561A0 (sv) 1994-09-30
JPH06217791A (ja) 1994-08-09
NO943653D0 (no) 1994-09-30
IL105145A0 (en) 1993-07-08
WO1993019785A1 (en) 1993-10-14
AU658987B2 (en) 1995-05-04
NO943653L (no) 1994-11-30
CA2093099A1 (en) 1993-10-02

Similar Documents

Publication Publication Date Title
KR950005327A (ko) 임파구 항원 CD2 및 종양 항원을 인식하는 이특이적 트리거(Trigger) 분자
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
DK0626447T3 (da) Monoklonale antistoffer og Fv, som er specifikke for CD2-antigen
DK1140170T3 (da) Antistoffragmenter til topisk behandling af öjensygdomme
AR045056A1 (es) Anticuerpos anti-ngf humanos neutralizantes como inhibidores selectivos de la via de ngf
BG99074A (en) Recombinant human hiv neutralizing monoclonal antibodies for prophylaxy and treatment of hiv infection
DE69609188D1 (de) Neutralisierende monoklonale antikörper gegen respiratorischen synzytialvirus
DK442788D0 (da) Fremgangsmaade og praeparat til behandling af non-ige-medierede lidelser
EA200601715A1 (ru) Получение гуманизированных антител в [организме] трансгенных животных
NO982062D0 (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav
ES2074042T3 (es) Exotoxina recombinante de pseudomonas construccion de una inmunotoxina activa con efectos secundarios menores.
RU2000124084A (ru) Химерное антитело, которое связывается с CD40 человека (варианты), молекула нуклеиновой кислоты (варианты), вектор экспрессии (варианты), гуманизированное антитело (варианты), фармацевтическая композиция для лечения заболевания, опосредованного Т-клетками (варианты), способ лечения больного от заболевания, опосредованного Т-клетками (варианты)
DK0702563T3 (da) Sammensætninger og fremgangsmåder til behandling af cancer og hyperproliferative sygdomme
RU2317998C2 (ru) Антитела человека, обладающие активностью связывания c mn и нейтрализации клеточной адгезии
BR9607171A (pt) Anticorpos monoclonais anti-cd6 e usos dos mesmos
OA07388A (fr) Nouveaux conjugués associant, par liaison convalente, une enzyme et un anticorps et associations médicamenteuses utilisant lesdits conjugués.
ES2194015T3 (es) Anticuerpos monoclonales humanos neutralizantes del virus de inmunodeficiencia humana.
DK0552296T3 (da) Monoklonale antistoffer fra mus
MC2308A1 (fr) Peptides utilises dans la vaccination et l'induction d'anticorps neutralisant contre le virus de l'immunodeficience humaine
DE69824234D1 (de) Menschliche-"CDR-grafted"-Antikörper gegen Gangliosid gm2
HUP0103573A2 (hu) Trombózis elleni hatóanyag és von Willebrand faktor elleni monoklonális antitest
DE69737323D1 (de) Adhesin aus heliobacter pylori, welches an blutgruppenantigene bindet
FI934145A (fi) Omformade monoklonala antikroppar mot en immunoglobulinisotyp
DE69841331D1 (de) Humanisierte monoklonale antikörper die schützen gegen shigatoxininduzierte krankheiten
BG96346A (bg) Специфични свързващи вещества